Nicholas Hertz

Dr. Hertz’s graduate research with Kevan Shokat provided the foundation for Mitokinin’s PINK1 program. Dr. Hertz leads a team of 12 scientists and research associates, along with 8 FTEs at CRO partners, pushing Mitokinin’s science and therapeutics forward. He has authored over 18 publications in journals such as Cell, Neuron and Nature. Dr. Hertz has been an invited speaker at international conferences including the Michael J. Fox Parkinson’s Disease Therapeutics Conference in 2018 and holds several patents.

Dr. Hertz received his Ph.D in Chemistry and Chemical Biology from UCSF with a Genentech graduate fellowship in the labs of Kevan Shokat and Al Burlingame. Following his Ph.D, he completed his post-doctoral training in neuroscience as a Helen Hay Whitney fellow in the lab of Marc Tessier-Lavigne at Stanford University. He graduated magna cum laude and Phi Beta Kappa from UCLA with a B.S. in Biochemistry.